Literature DB >> 26692952

Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.

Yiying Wang1, Li Li2, Yue Wang3, Sarah Ngocvi Tang4, Wenxin Zheng5.   

Abstract

Recent advances suggest that precancerous lesions of pelvic serous carcinoma originate from tubal secretory cells. The purpose of our study was to determine if an increased number of secretory cells varies with age or location in the fallopian tube and to examine its association with serous neoplasia. Three groups (benign control, high-risk, and pelvic serous carcinoma) of age-matched patients were studied. The age data were stratified into 10-year intervals ranging from 20-29 to older than 80. The number of secretory and ciliated cells from both tubal fimbria and ampulla segments was counted by microscopy and immunohistochemical staining methods. The data were analyzed by standard contingency table and Poisson distribution methods after age justification. We found that the absolute number of tubal secretory cells increased significantly with age in all three groups. But a more dramatic increase of secretory cells was observed in high-risk and pelvic serous carcinoma patients. Secretory cell expansion is more prevalent than secretory cell outgrowth in both fimbria and ampulla tubal segments and is significantly associated with serous neoplasia (P < 0.001). Furthermore, age remained a significant risk factor for serous neoplasia after age adjustment. These findings suggest that secretory cell expansion could serve as a potential sensitive biomarker for early serous carcinogenesis within the fallopian tube. The study also supports a relationship between serous neoplasia and increased secretory to ciliated cell ratios, and the relationship between frequency of secretory cell expansion within the fallopian tube and increasing age and-more significantly-presence of high-risk factors or co-existing serous cancers.

Entities:  

Keywords:  Fallopian tube; carcinogenesis; ovarian cancer; pathogenesis; pelvic serous carcinoma; tubal secretory cells

Year:  2015        PMID: 26692952      PMCID: PMC4656785     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  38 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

Review 2.  Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum).

Authors:  Deborah Delair; Robert A Soslow
Journal:  Histopathology       Date:  2012-02-28       Impact factor: 5.087

Review 3.  The distal fallopian tube: a new model for pelvic serous carcinogenesis.

Authors:  Christopher P Crum; Ronny Drapkin; Alexander Miron; Tan A Ince; Michael Muto; David W Kindelberger; Yonghee Lee
Journal:  Curr Opin Obstet Gynecol       Date:  2007-02       Impact factor: 1.927

4.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

Review 5.  The oviduct and ovarian cancer: causality, clinical implications, and "targeted prevention".

Authors:  Christopher P Crum; Frank D McKeon; Wa Xian
Journal:  Clin Obstet Gynecol       Date:  2012-03       Impact factor: 2.190

Review 6.  Precursors to pelvic serous carcinoma and their clinical implications.

Authors:  Ann K Folkins; Elke A Jarboe; Michael H Roh; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-02-23       Impact factor: 5.482

Review 7.  Prevention of ovarian cancer: intraepithelial neoplasia.

Authors:  Molly A Brewer; Karen Johnson; Michele Follen; David Gershenson; Robert Bast
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

Review 8.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

9.  Serous carcinogenesis in the fallopian tube: a descriptive classification.

Authors:  Elke Jarboe; Ann Folkins; Marisa R Nucci; David Kindelberger; Ronny Drapkin; Alexander Miron; Yonghee Lee; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2008-01       Impact factor: 2.762

10.  Secretory cell expansion with aging: risk for pelvic serous carcinogenesis.

Authors:  Jie Li; Yan Ning; Nisreen Abushahin; Zeng Yuan; Yiying Wang; Yue Wang; Bingbing Yuan; Janiel M Cragun; Setsuko K Chambers; Kenneth Hatch; Beihua Kong; Wenxin Zheng
Journal:  Gynecol Oncol       Date:  2013-09-20       Impact factor: 5.482

View more
  7 in total

Review 1.  The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.

Authors:  Sabrina J Ritch; Carlos M Telleria
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

2.  Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.

Authors:  Nur Yucer; Rodney Ahdoot; Michael J Workman; Alexander H Laperle; Maria S Recouvreux; Kathleen Kurowski; Diana J Naboulsi; Victoria Liang; Ying Qu; Jasmine T Plummer; Simon A Gayther; Sandra Orsulic; Beth Y Karlan; Clive N Svendsen
Journal:  Cell Rep       Date:  2021-12-28       Impact factor: 9.423

3.  LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions.

Authors:  Elisa Schmoeckel; Ashley A Odai-Afotey; Michael Schleißheimer; Miriam Rottmann; Andrea Flesken-Nikitin; Lora H Ellenson; Thomas Kirchner; Doris Mayr; Alexander Yu Nikitin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

4.  Focal Serous Tubal Intra-Epithelial Carcinoma Lesions Are Associated With Global Changes in the Fallopian Tube Epithelia and Stroma.

Authors:  Jingni Wu; Yael Raz; Maria Sol Recouvreux; Márcio Augusto Diniz; Jenny Lester; Beth Y Karlan; Ann E Walts; Arkadiusz Gertych; Sandra Orsulic
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 5.738

5.  Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution.

Authors:  Xuexin Yu; Wanrun Lin; Alexandra Spirtos; Yan Wang; Hao Chen; Jianfeng Ye; Jessica Parker; Ci Ci Liu; Yiying Wang; Gabriella Quinn; Feng Zhou; Setsuko K Chambers; Cheryl Lewis; Jayanthi Lea; Bo Li; Wenxin Zheng
Journal:  BMC Med       Date:  2022-09-09       Impact factor: 11.150

6.  Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma.

Authors:  Tiziana de Cristofaro; Tina Di Palma; Amata Amy Soriano; Antonella Monticelli; Ornella Affinito; Sergio Cocozza; Mariastella Zannini
Journal:  Oncotarget       Date:  2016-07-05

7.  STING pathway expression in low-grade serous carcinoma of the ovary: an unexpected therapeutic opportunity?

Authors:  Jutta Huvila; Dawn R Cochrane; Monica Ta; Christine Chow; Kendall Greening; Samuel Leung; Anthony N Karnezis; Analisa DiFeo; David G Huntsman
Journal:  J Pathol Clin Res       Date:  2021-06-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.